海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002099 海翔药业

已收盘 01-23 15:00:00

{"stockData":{"symbol":"002099","market":"SZ","secType":"STK","nameCN":"海翔药业","latestPrice":6.57,"timestamp":1769151834000,"preClose":6.43,"halted":0,"volume":24261309,"delay":0,"changeRate":0.0218,"floatShares":1616000000,"shares":1619000000,"eps":-0.207,"marketStatus":"已收盘","change":0.14,"latestTime":"01-23 15:00:00","open":6.44,"high":6.64,"low":6.44,"amount":158000000,"amplitude":0.0311,"askPrice":6.57,"askSize":476,"bidPrice":6.56,"bidSize":420,"shortable":0,"etf":0,"ttmEps":-0.207,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769391000000},"marketStatusCode":5,"adr":0,"adjPreClose":6.43,"symbolType":"stock","openAndCloseTimeList":[[1769131800000,1769139000000],[1769144400000,1769151600000]],"highLimit":7.07,"lowLimit":5.79,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1618715253,"isCdr":false,"pbRate":2.03,"roa":"--","roe":"0.14%","epsLYR":-0.21,"committee":0.145218,"marketValue":10635000000,"turnoverRate":0.015,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-26。","floatMarketCap":10615000000},"requestUrl":"/m/hq/s/002099","defaultTab":"news","newsList":[{"id":"2605217292","title":"海翔药业：截止1月20日公司股东人数为30934人","url":"https://stock-news.laohu8.com/highlight/detail?id=2605217292","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605217292?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:54","pubTimestamp":1768985650,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：截至1月20日公司的股东人数为多少？海翔药业回复：您好，截止1月20日公司股东人数为30934人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100027322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0077","BK0188","BK0028","BK0192","BK0239"],"gpt_icon":0},{"id":"2604305131","title":"股市必读：海翔药业（002099）1月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604305131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604305131?lang=zh_cn&edition=full","pubTime":"2026-01-20 01:58","pubTimestamp":1768845490,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，海翔药业报收于6.54元，上涨0.31%，换手率1.22%，成交量19.67万手，成交额1.28亿元。公司公告汇总关于参投合伙企业投资复宏汉霖的进展公告浙江海翔药业股份有限公司出资1亿元参与设立杭州复宏股权投资合伙企业，专项投资于复宏汉霖的非上市股份。2026年1月19日，公司收到合伙企业通知，复宏汉霖已获中国证监会备案，其部分股东持有的境内未上市股份将转为H股并在香港联交所上市流通。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000000793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0077","BK0239","002099","BK0188","BK0028"],"gpt_icon":0},{"id":"2603660218","title":"海翔药业：截至1月9日股东人数为31210人","url":"https://stock-news.laohu8.com/highlight/detail?id=2603660218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603660218?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:31","pubTimestamp":1768375874,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：截至1月9日公司股东人数为多少？海翔药业回复：您好，截止1月9日公司股东人数为31210人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","002099","BK0239","BK0188","BK0192"],"gpt_icon":0},{"id":"2603660229","title":"海翔药业：参投基金持有天兵科技1.352%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2603660229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603660229?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:27","pubTimestamp":1768375638,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好！根据相关AI检索，贵公司通过某投资基金，参投了两家商业航天公司的相关股权。请介绍一下具体情况，穿透股权比例，及后续相关投资安排等。谢谢！海翔药业回复：您好，公司参投的寓鑫基金分别持有天兵科技和爱思达航天的1.352%股权和2.83%股权。根据公开信息，两家公司已启动了IPO辅导。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0239","002099","BK0188","BK0192"],"gpt_icon":0},{"id":"2603657187","title":"海翔药业：公司未持有星河动力股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2603657187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603657187?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:35","pubTimestamp":1768275305,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月13日在投资者关系平台上答复投资者关心的问题。投资者提问：网传公司持有星河动力股票是否属实？如有请告知占股比例多少！谢谢海翔药业回复：您好，公司未持有星河动力股票。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300016068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002099","BK0077","BK0192","BK0188"],"gpt_icon":0},{"id":"2602469615","title":"海翔药业（002099）披露签订创新药合作协议，1月12日股价上涨3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602469615","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602469615?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:32","pubTimestamp":1768228336,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，海翔药业报收于7.4元，较前一交易日上涨3.06%，最新总市值为119.78亿元。近日，浙江海翔药业股份有限公司与万邦德制药集团有限公司签订《创新药合作协议》。海翔药业作为资金提供方，将投入1.5亿元人民币，获得WP205产品全球商业化收益的15%。若2027年6月30日前未能启动III期临床或获得上市许可，海翔药业有权终止协议，万邦德制药需返还全部款项并支付年化3%资金使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200037474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","06978","BK0028","BK0077","BK0188","BK1161","BK0192","BK0239","002099"],"gpt_icon":0},{"id":"2602519380","title":"海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519380","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602519380?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215702,"startTime":"0","endTime":"0","summary":"海翔药业(002099.SZ)公告称，公司与万邦德制药签订《创新药合作协议》，双方将围绕渐冻症适应症开展相关合作，包括WP205产品的研发和商业化。海翔药业将提供1.5亿元资金，并享有产品商业化后15%的收益权益。该协议需经万邦德医药控股集团股份有限公司股东会审议通过后生效。存在法规政策、市场环境等风险，以及药品研发的高风险特点。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200029909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","002082","BK0188","BK0077","159992","BK0004","BK0028","BK1191","01477","BK0050","BK0239","002099","BK1161","BK0192"],"gpt_icon":0},{"id":"2601338955","title":"海翔药业：参投基金持有爱思达2.83%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2601338955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601338955?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:55","pubTimestamp":1767833708,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问贵公司是否投资参股了爱思达航天公司？大概有多少股份？海翔药业回复：您好，公司参投的寓鑫基金持有天津爱思达航天科技股份有限公司2.83%股权。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800006225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0239","002099","BK0077","BK0028","BK0188"],"gpt_icon":0},{"id":"2601564978","title":"海翔药业：持有寓鑫基金约10.69%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2601564978","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601564978?lang=zh_cn&edition=full","pubTime":"2026-01-06 08:33","pubTimestamp":1767659589,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，公司参投的基金持有天兵科技1.352%股份，目前公司持有该基金的份额大约多少或者占多少比例？海翔药业回复：您好，公司持有寓鑫基金约10.69%股权。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600006859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002099","BK0188","BK0077","BK0192"],"gpt_icon":0},{"id":"2601000914","title":"海翔药业（002099）披露股份回购进展情况，1月5日股价上涨3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000914?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:14","pubTimestamp":1767608098,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，海翔药业报收于6.43元，较前一交易日上涨3.04%，最新总市值为104.08亿元。该股当日开盘6.27元，最高6.72元，最低6.27元，成交额达2.98亿元，换手率为2.84%。公司近日发布公告，披露了关于股份回购的进展情况。浙江海翔药业股份有限公司于2025年4月9日召开董事会，审议通过回购股份方案，拟使用自有/自筹资金通过集中竞价交易方式回购公司股份，用于股权激励或员工持股计划。回购进展符合相关规定和既定方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500028104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","002099","BK0028","BK0192","BK0239"],"gpt_icon":0},{"id":"2595788890","title":"海翔药业(002099.SZ)参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788890","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595788890?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:11","pubTimestamp":1766995885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业 发布公告，公司近日收到旗下产业基金管理人北京国信中数投资管理有限公司出具的《通知函》。NWRD06注射液是目前全球首个针对肝癌特异性靶点GPC3并进入Ⅱ期临床阶段的治疗性核酸药物，其通过激活特异性T细胞免疫清除肿瘤细胞的机制具有创新性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK0077","BK1574","BK0028","BK1161","BK0239","159992","002099","BK0188","BK0192"],"gpt_icon":0},{"id":"2593349840","title":"海翔药业：截止12月19日公司股东人数为27172人","url":"https://stock-news.laohu8.com/highlight/detail?id=2593349840","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593349840?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:31","pubTimestamp":1766478670,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月20日股东人数是多少？海翔药业回复：您好，截止12月19日公司股东人数为27172人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300023606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0192","BK0077","002099","BK0028"],"gpt_icon":0},{"id":"2592787905","title":"海翔药业：研发经费分期支付不构成重大影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2592787905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592787905?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:51","pubTimestamp":1766062270,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业12月17日在投资者关系平台上答复投资者关心的问题。海翔药业回复：您好，根据《合作协议》规定，在合作期限内，研发经费将根据具体的合作项目按进度分期支付，不会对公司2025年度的财务状况、经营成果构成重大影响。国科大杭高院相关研究团队此前与产业界已有科研成果转化的成功案例，实际贡献经济效益。根据《深圳证券交易所股票上市规则》，公司目前不存在任何触及退市风险的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800035339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0192","BK0077","BK0028","002099"],"gpt_icon":0},{"id":"2592995768","title":"海翔药业(002099.SZ)：NWRD08注射液完成Ⅱ期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995768","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592995768?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:58","pubTimestamp":1765965522,"startTime":"0","endTime":"0","summary":"公告显示，NWRD08注射液是我国自主研发的首个针对HPV16/18阳性宫颈高级别鳞状上皮内病变进入Ⅱ期临床阶段的新一代治疗性核酸药物，其通过激活特异性T细胞免疫清除感染细胞。与预防性HPV疫苗不同，其专门针对已感染HPV并出现相关病变的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海翔药业(002099.SZ)：NWRD08注射液完成Ⅱ期临床首例受试者入组","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0077","002099","BK0239","BK0188","BK0192"],"gpt_icon":0},{"id":"2590567748","title":"海翔药业：截止12月10日公司股东人数为27495人","url":"https://stock-news.laohu8.com/highlight/detail?id=2590567748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590567748?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:07","pubTimestamp":1765436843,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：截至12月10日股东人数为多少？海翔药业回复：您好，截止12月10日公司股东人数为27495人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0239","BK0077","BK0028","BK0192","BK0188"],"gpt_icon":0},{"id":"2590464903","title":"海翔药业：公司目前经营情况正常且现金流健康稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2590464903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590464903?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:51","pubTimestamp":1765284677,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：1，公司目前现金流情况，后续并购项目的考虑？2，公司行业整体情况以及公司在手订单情况？请详告。海翔药业回复：您好，公司目前经营情况正常且现金流健康稳健，未来如有并购相关计划，将严格按照相关法律法规及时履行信息披露义务。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900037416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159399","002099","BK0239","BK0077","BK0192","BK0028","BK0188"],"gpt_icon":0},{"id":"2590316879","title":"海翔药业(002099.SZ)拟与杭高院共建先进合成技术产业研究院","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316879","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590316879?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:18","pubTimestamp":1765268289,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业(002099.SZ)公告，公司与国科大杭州高等研究院(简称“杭高院”)签署了《共建先进合成技术产业研究院合作协议》，产业研究院的研发方向主要聚焦医药原料药、中间体、染料、新材料的开发与工业化等，合作总金额5000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海翔药业(002099.SZ)拟与杭高院共建先进合成技术产业研究院","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002099","BK0239","BK0077","BK0192","BK0028","BK0188"],"gpt_icon":0},{"id":"2589338424","title":"海翔药业：生产基地主要分布在台州地区","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589338424?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:15","pubTimestamp":1765181715,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司目前的产能分布及产能利用率情况？海翔药业回复：您好，公司目前生产基地主要分布在台州地区，当前生产经营活动正常有序，在手订单储备与客户需求节奏相匹配，产能利用率维持在合理水平。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800015519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0077","BK0239","002099","BK0188","BK0028"],"gpt_icon":0},{"id":"2588742084","title":"海翔药业：截止11月28日公司股东人数为27406人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588742084","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588742084?lang=zh_cn&edition=full","pubTime":"2025-12-01 15:57","pubTimestamp":1764575835,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：截至11月28日公司的股东人数为多少？海翔药业回复：您好，截止11月28日公司股东人数为27406人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100013550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0028","BK0239","002099","BK0192"],"gpt_icon":0},{"id":"2586023425","title":"海翔药业：参投基金持有天兵科技1.352%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2586023425","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586023425?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:33","pubTimestamp":1764145990,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业11月26日在投资者关系平台上答复投资者关心的问题。海翔药业回复：您好，公司参投的寓鑫基金持有天兵科技1.352%股权，该基金投资项目还涉及航天航空材料、金属新材料、医药研发、高端设备制造、芯片制造等领域。此外公司投资设立的产业基金北京国信海翔参投了部分创新药项目，涉及HPV感染及肝癌治疗性疫苗、TCR-T细胞治疗、重组巴曲酶等领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600021931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0077","BK0188","BK0239","002099","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769185312546,"stockEarnings":[{"period":"1week","weight":0.0077},{"period":"1month","weight":0.0914},{"period":"3month","weight":0.1486},{"period":"6month","weight":0.0718},{"period":"1year","weight":0.3631},{"period":"ytd","weight":0.0529}],"compareEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":0.0495},{"period":"3month","weight":0.047},{"period":"6month","weight":0.151},{"period":"1year","weight":0.2805},{"period":"ytd","weight":0.0422}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30934人(较上一季度减少0.88%)","perCapita":"52230股","listingDate":"2006-12-26","address":"浙江省台州市椒江区外沙支路100号","registeredCapital":"161871万元","survey":"　　浙江海翔药业股份有限公司的主营业务是医药及染料全产业链业务。公司的主要产品是原料药及医药中间体、合同定制业务、制剂、染料及染颜料中间体。公司已承担完成国家级项目13项，省级项目35项，拥有国内发明专利61项、PCT专利4项，荣获浙江省级科技奖项11项。","listedPrice":11.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海翔药业,002099,海翔药业股票,海翔药业股票老虎,海翔药业股票老虎国际,海翔药业行情,海翔药业股票行情,海翔药业股价,海翔药业股市,海翔药业股票价格,海翔药业股票交易,海翔药业股票购买,海翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}